Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00665353 · ClinicalTrials.gov registry record · Phase 2
Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance
A Phase 2 study of HIV-1 and Hepatitis C Co-Infection, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 8
- Study locations
NCT00665353: Completed Phase 2 study of HIV-1 and Hepatitis C Co-Infection, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
NCT00665353 is a Phase 2 study of HIV-1 and Hepatitis C Co-Infection that has completed, run by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. The registered enrollment target is 19 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00665353, a Phase 2 study of HIV-1 and Hepatitis C Co-Infection, has completed, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 8
- Study locations
Study Summary
Insulin resistance is common in people coinfected with HIV and Hepatitis C virus (HCV) and is associated with poor responses to treatment for HCV. Pioglitazone is an FDA-approved medication for the treatment of type 2 diabetes. It works by increasing the body's sensitivity to insulin. The purpose of this study is to determine whether treatment with pioglitazone prior to HCV treatment with peginterferon and ribavirin is safe and effective in improving the treatment outcome in insulin-resistant, HIV/HCV-coinfected people for whom previous treatment with peginterferon and ribavirin was unsuccessful.
Conditions Studied
Interventions
- DRUG pioglitazone
- DRUG peginterferon
- DRUG ribavirin
Study Locations (8)
New York
- Cornell CRS (7804) - New York
- NY Univ. HIV/AIDS CRS (401) - New York
- AIDS Care CRS (1108) - Rochester
California
- Ucsf Aids Crs (801) - San Francisco
Illinois
- Northwestern University CRS (2701) - Chicago
New Jersey
- New Jersey Medical School-Adult Clinical Research Ctr. CRS (31477) - Newark
Ohio
- Metro Health CRS (2503) - Cleveland
Virginia
- Virginia Commonwealth Univ. Medical Ctr. CRS (31475) - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
What the finished NCT00665353 record still lists
NCT00665353 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 1 condition, with HIV-1 and Hepatitis C Co-Infection appearing as the primary indexed condition, and to 3 interventions - of which pioglitazone is the first listed.
NCT00665353 lists 8 locations in 6 states (New York, California, Illinois).
Frequently Asked Questions
What is clinical trial NCT00665353 about?
NCT00665353 is a clinical study titled "Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance". Insulin resistance is common in people coinfected with HIV and Hepatitis C virus (HCV) and is associated with poor responses to treatment for HCV. Pioglitazone is an FDA-approved medication for the treatment of type 2 diabetes. It works by increasing the body's sensitivity to insulin. The purpose of...
What is the current status of trial NCT00665353?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2009-03. Estimated completion is 2011-12.
What conditions does trial NCT00665353 study?
This clinical trial studies the following conditions: HIV-1 and Hepatitis C Co-Infection.
What interventions are being tested in trial NCT00665353?
The interventions under investigation include: pioglitazone (DRUG), peginterferon (DRUG), ribavirin (DRUG).
Who is sponsoring clinical trial NCT00665353?
This trial is sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00665353 being conducted?
This trial has 8 study locations across California, Illinois, New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00665353's enrollment target sits among peer trials
19 1894th of 2000 higher than 103 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia